The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: A propensity score analysis

Arthritis Care and Research

Volumn 59, Issue 7, 2008, Pages 989-995

  Seshadri, Roopa ^a   Feldman, Brian M ^b   Ilowite, Norman ^c   Cawkwell, Gail ^d,e   Pachman, Lauren M ^f,g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e JOHNS HOPKINS ALL CHILDREN S HOSPITAL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ARTICLE; CALCIFICATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; RANGE OF MOTION; RETROSPECTIVE STUDY;

ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; PREDNISONE; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 47249109482     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23829     Document Type: Article

References (37)

1. Mendez EP, Lipton R, Ramsey-Goldman R, Roettcher P, Bowyer S, Dyer A, et al, for the NIAMS Juvenile DM Registry Physician Referral Group. US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry. Arthritis Rheum 2003;49:300-5.
2. Pachman LM, Hayford JR, Chung A, Daugherty CA, Pallansch MA, Fink CW, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol 1998;25:1198-204.
3. Ramanan AV, Feldman BM. Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes. Rheum Dis Clin North Am 2002;28:833-57.
4. Bitnum S, Daeschner CW Jr, Travis LB, Dodge WF, Hopps HC. Dermatomyositis. J Pediatr 1964;64:101-31.
5. Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol 2002;47:505-11.
6. Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrel PN. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum 2005;52:3570-8.
7. Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr 1983;103:882-8.
8. Callen AM, Pachman LM, Hayford J, Chung A, Ramsey-Goldman R. Intermittent high-dose intravenous methylprednisolone (IV pulse) therapy prevents calcinosis and shortens disease course in juvenile dermatomyositis (JDMS) [abstract]. Arthritis Rheum 1994;37 Suppl 6:R10.
9. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
10. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [published erratum appears in Lancet 1998;351:220]. Lancet 1997;350:309-18.
11. Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis. J Rheumatol 2001;28:2230-7.
12. Feduska NJ, Turcotte JG, Gikas PW, Bacon GE, Penner JA. Reversal of renal allograft rejection with intravenous methylprednisolone "pulse" therapy. J Surg Res 1972;12:208-15.
13. Kimberly RP. Pulse methylprednisolone in SLE. Clin Rheum Dis 1982;8:261-78.
14. Smith MD, Ahem MJ, Roberts-Thomson PJ, Smith MD. Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment? Ann Rheum Dis 1990;49:265-7.
15. Klein-Gitelman MS, Waters T, Pachman LM. The economic impact of intermittent high-dose intravenous versus oral corticosteroid treatment of juvenile dermatomyositis. Arthritis Care Res 2000;13:360-8.
16. Rouster-Stevens KA, Gursahaney A, Ngai KL, Daru JA, Pachman LM. Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum 2008;59:222-6.
17. Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol 2005;59:663-9.
18. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98.
19. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
20. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
21. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996;52:249-64.
22. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 2007;39:33-8.
23. Gum PA, Thamilarasan M, Watanabe J, Blackstone EH, Lauer MS. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001;286:1187-94.
24. Kaur S, Stechuchak KM, Coffman CJ, Allen KD, Bastian LA. Gender differences in health care utilization among veterans with chronic pain. J Gen Intern Med 2007;22:228-33.
25. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
26. Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, et al. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry. Arthritis Rheum 2005;53:166-72.
27. Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, et al. Duration of illness is an important variable for untreated children with juvenile dermatomyositis. J Pediatr 2006;148:247-53.
28. Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease activity score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:7-15.
29. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
30. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
31. Jordan CD, Flood JG, Laposata M, Lewandrowski KB. Normal reference laboratory values. N Engl J Med 1992;327:718-24.
32. Ruperto N, Ravelli A, Murray KJ, Lovell DJ, Andersson-Gare B, Feldman BM, et al, the Pediatric Rheumatology International Trials Organization (PRINTO), and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Preliminary core sets of measures for disease activity and damage for juvenile systemic lupus erythematosus and juvenile dermatomyositis. Rheumatology (Oxford) 2003;42:1452-9.
33. Bergstralh EJ, Kosanke JL. Computerized matching of controls. Rochester (MN): Mayo Foundation; 1995.
34. Bergstralh E, Kosanke J. SAS macros: gmatch program. 2004. URL: http://mayoresearch.mayo.edu/mayo/research/biostat/upload/gmatch.sas.
35. Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum 1992;35:1143-9.
36. Christen-Zaech S, Seshadri R, Sundberg J, Abbott K, Paller AS, Pachman LM. Juvenile dermatomyositis: persistent association of nailfold capillaroscopy changes and skin involvement over 36 months with duration of untreated disease. Arthritis Rheum. In press.
37. Pachman LM, Veis A, Stock S, Abbott K, Vicari F, Patel P, et al. Composition of calcifications in children with juvenile dermatomyositis: association with chronic cutaneous inflammation. Arthritis Rheum 2006;54:3345-50.